Seroepidemiological evidence for an association between Chlamydia pneumoniae and atherosclerosis.
The respiratory pathogen Chlamydia pneumoniae has been implicated in the pathogenesis of coronary heart disease. Evidence for this includes the direct demonstration of the organism in atherosclerotic plaques and the results of seroepidemiological studies. Of the several serological tests available, the microimmunofluorescence (MIF) test is the most widely used and has become a 'gold standard' because of its specificity and selectivity. In spite of differences in serological criteria of infection and interpretation, the findings of various research groups who have used the MIF test have suggested a link between atherosclerotic cardiovascular disease and Chlamydia pneumoniae infection. Further research is now required in accordance with standard criteria and using pre-defined techniques to confirm the role of the organism in coronary heart disease.
Orfila
J J
JJ
Laboratory of General Bacteriology and Immunology, Amiens Regional Hospital Centre, France.
D001161:Arteriosclerosis / Q000453:epidemiology / Q000382:microbiology*; D002690:Chlamydia Infections / Q000150:complications / Q000175:diagnosis* / Q000453:epidemiology; D016993:Chlamydophila pneumoniae / Q000302:isolation & purification*; D002908:Chronic Disease; D003324:Coronary Artery Disease / Q000453:epidemiology / Q000382:microbiology; D006801:Humans; D015994:Incidence; D011379:Prognosis; D012307:Risk Factors; D016036:Seroepidemiologic Studies; D012698:Serologic Tests